CJC-1295 with DAC
Men's HealthMen's-health clinics treat CJC-1295 with DAC as one component in a layered hormonal optimisation framework. A long-acting growth-hormone-releasing-hormone analogue with a Drug Affinity Complex that extends half-life to roughly a week. The relevant questions for male users are: does it interact with the HPG axis, is it compatible with current TRT or HCG protocols, and what are its effects on prostate, hematocrit, and cardiovascular indices over a ~6-8 days (with DAC)-pharmacokinetics CJC-1295 with DAC cycle? The sections below address each.
Key Takeaways
Male-physiology lens: CJC-1295 with DAC is evaluated against HPG-axis interaction, TRT compatibility, and prostate / cardiovascular considerations. Mechanism: Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release. Male monitoring: baseline testosterone (total/free), LH, FSH, estradiol, prolactin, SHBG; 6-8 week follow-up panel. Male dose: 1-2 mg 1-2x weekly via subq; cycle 8-12 weeks. Male-physiology stack partners: Kisspeptin, Gonadorelin (GnRH), PT-141.
Male users' practical questions about CJC-1295 with DAC reduce to: hormonal coherence, TRT integration, and prostate / cardiovascular safety. Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release. The maleimide-based Drug Affinity Complex (DAC) tail covalently binds serum albumin, extending half-life from minutes to days. Stimulates pulsatile GH secretion that elevates baseline IGF-1. The mechanism shapes the answer to each. The subsections below work through HPG-axis impact and TRT compatibility before examining the body composition and male-physiology response.
Male body composition and performance response
Male users typically respond to CJC-1295 with DAC on the recovery, lean-mass, or visceral-fat dimension depending on the compound's primary pharmacology. Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release. The maleimide-based Drug Affinity Complex (DAC) tail covalently binds serum albumin, extending half-life from minutes to days. Stimulates pulsatile GH secretion that elevates baseline IGF-1. For men whose body composition goals are driven by training, the dose-timing relative to workouts and sleep is often the critical lever rather than the absolute dose itself.
Compatibility with TRT and post-cycle protocols
For men currently on TRT or planning a post-cycle restart, CJC-1295 with DAC is typically compatible because it operates on a separate (somatotrophic) axis. The dominant interaction to watch for is on the metabolic and recovery layers rather than the hormonal layer. Where the molecule's pharmacology overlaps with HCG, gonadorelin, or kisspeptin, dose layering is the standard approach.
Interaction with the HPG axis
CJC-1295 with DAC's relationship to the male HPG axis is one of the central practical questions. The molecule directly engages the axis through its receptor pharmacology. The practical takeaway is that any male user beginning a course of CJC-1295 with DAC should have a baseline hormone panel and a follow-up at 6–8 weeks to detect drift.
Where male users target trt compatibility, CJC-1295 with DAC is typically integrated with the broader hormonal protocol — TRT, kisspeptin, gonadorelin, or HCG — rather than used in isolation. The integration approach varies by clinic.
For prostate health in male users, CJC-1295 with DAC is most-effective when paired with comprehensive labs (testosterone total/free, LH, FSH, estradiol sensitive, prolactin, SHBG) at baseline and follow-up. Cycle length 8–12 weeks with re-evaluation.
Testosterone Optimisation in men responds to CJC-1295 with DAC with effect sizes that vary substantially by baseline status — men with documented suboptimal status respond more strongly than those at the upper end of normal. The protocol pattern in clinical use reflects this.
Where male users target libido, CJC-1295 with DAC is typically integrated with the broader hormonal protocol — TRT, kisspeptin, gonadorelin, or HCG — rather than used in isolation. The integration approach varies by clinic.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 1-2 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 1-2 mg | 4–6 weeks initial cycle |
| Men's Health focus | SubQ | 1-2 mg | 1-2x weekly |
| Maintenance phase | SubQ | 1-2 mg | Ongoing with periodic pauses |
Dose timing for CJC-1295 with DAC is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.
CJC-1295 with DAC stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from men's-health clinicians.
- CJC-1295 with DAC + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with CJC-1295 with DAC's mechanism in male physiology protocols.
- CJC-1295 with DAC + Gonadorelin (GnRH): Binds the GnRH receptor on anterior pituitary gonadotrophs in a pulsatile fashion to stimulate LH (and to a lesser extent FSH) release. Pairs naturally with CJC-1295 with DAC's mechanism in male physiology protocols.
- CJC-1295 with DAC + PT-141: Activates MC4R in the hypothalamus and other CNS regions involved in sexual response. Pairs naturally with CJC-1295 with DAC's mechanism in male physiology protocols.
- CJC-1295 with DAC + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with CJC-1295 with DAC's mechanism in male physiology protocols.
Sustained IGF-1 elevation; monitor in users at risk of malignancy. Site reactions, transient flushing, water retention possible.
Lens-specific safety considerations for male physiology use of CJC-1295 with DAC: Sustained IGF-1 elevation; monitor in users at risk of malignancy. Site reactions, transient flushing, water retention possible. Additional male physiology monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| CJC-1295 with DAC | Long-acting GHRH analogue | ~6-8 days (with DAC) | Men's Health |
| Kisspeptin | Hypothalamic upstream regulator of GnRH | ~28 min IV | The upstream master regulator of GnRH neurons — driving the entire HPG axis from above |
| Gonadorelin (GnRH) | Hypothalamic decapeptide | ~2-4 min | The natural decapeptide that drives pituitary release of LH and FSH — used clinically and increasingly as an HCG alternative during testosterone therapy |
| PT-141 | Melanocortin receptor agonist | ~2-3 hr | An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women |
Does CJC-1295 with DAC affect hair, prostate, or erythrocyte production?
What blood work should I run on this protocol?
Is CJC-1295 with DAC compatible with TRT?
Can I use CJC-1295 with DAC during a cut?
What class of compound is CJC-1295 with DAC?
How long until I see results from CJC-1295 with DAC?
Start a CJC-1295 with DAC Protocol
Alukard provides physician-supervised men's health protocols with GMP-certified CJC-1295 with DAC and GMP-certified compounds with comprehensive hormone panels.
Get ProtocolQuick Facts
- Molecular weight
- ~3367 Da
- Sequence length
- 30 aa
- Half-life
- ~6-8 days (with DAC)
- WADA
- Banned (S2 class)
- FDA
- Unapproved
- Research
- Phase II human data; widely used off-label
All male physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for CJC-1295 with DAC unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Male Physiology Protocol for CJC-1295 with DAC
Alukard provides physician-supervised men's health protocols with GMP-certified compounds with comprehensive hormone panels.
HIPAA Compliant · GMP Certified · Physician Supervised